On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2

O. Caffo, V. Zagonel, C. Baldessari, A. Berruti, R. Bortolus, S. Buti, G.L. Ceresoli, M. Donini, P. Ermacora, G. Fornarini, L. Fratino, C. Masini, F. Massari, A. Mosca, C. Mucciarini, G. Procopio, M. Tucci, E. Verri, P. Zucali, C. Buttigliero

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)1415-1416
Number of pages2
JournalAnn. Oncol.
Volume31
Issue number10
DOIs
Publication statusPublished - 2020

Keywords

  • abiraterone
  • cabazitaxel
  • docetaxel
  • enzalutamide
  • antiandrogen
  • androgen deprivation therapy
  • cancer mortality
  • cancer recurrence
  • cancer registry
  • castration resistant prostate cancer
  • coronavirus disease 2019
  • human
  • infection risk
  • Letter
  • priority journal
  • prostate cancer
  • Severe acute respiratory syndrome coronavirus 2
  • Betacoronavirus
  • Coronavirus infection
  • male
  • pandemic
  • prostate tumor
  • severe acute respiratory syndrome
  • virus pneumonia
  • Androgen Antagonists
  • Coronavirus Infections
  • Humans
  • Male
  • Pandemics
  • Pneumonia, Viral
  • Prostatic Neoplasms
  • Severe Acute Respiratory Syndrome

Cite this